Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1097/SHK.0000000000001610

http://scihub22266oqcxt.onion/10.1097/SHK.0000000000001610
suck pdf from google scholar
32604223!8162895!32604223
unlimited free pdf from europmc32604223    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid32604223      Shock 2020 ; 54 (5): 586-594
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Therapeutic Potential of B-1a Cells in COVID-19 #MMPMID32604223
  • Aziz M; Brenner M; Wang P
  • Shock 2020[Nov]; 54 (5): 586-594 PMID32604223show ga
  • Coronavirus disease 2019 (COVID-19) is a life-threatening respiratory illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its clinical presentation can vary from the asymptomatic state to acute respiratory distress syndrome (ARDS) and multi-organ dysfunction. Due to our insufficient understanding of its pathophysiology and lack of effective treatment, the morbidity and mortality of severe COVID-19 patients are high. Patients with COVID-19 develop ARDS fueled by exaggerated neutrophil influx into the lungs and cytokine storm. B-1a cells represent a unique subpopulation of B lymphocytes critical for circulating natural antibodies, innate immunity, and immunoregulation. These cells spontaneously produce natural IgM, interleukin (IL)-10, and granulocyte-monocyte colony stimulating factor (GM-CSF). Natural IgM neutralizes viruses and opsonizes bacteria, IL-10 attenuates the cytokine storm, and GM-CSF induces IgM production by B-1a cells in an autocrine manner. Indeed, B-1a cells have been shown to ameliorate influenza virus infection, sepsis, and pneumonia, all of which are similar to COVID-19. The recent discovery of B-1a cells in humans further reinforces their potentially critical role in the immune response against SARS-CoV-2 and their anticipated translational applications against viral and microbial infections. Given that B-1a cells protect against ARDS via immunoglobulin production and the anti-COVID-19 effects of convalescent plasma treatment, we recommend that studies be conducted to further examine the role of B-1a cells in the pathogenesis of COVID-19 and explore their therapeutic potential to treat COVID-19 patients.
  • |*Adoptive Transfer/adverse effects[MESH]
  • |Animals[MESH]
  • |B-Lymphocyte Subsets/immunology/*transplantation[MESH]
  • |Betacoronavirus/immunology/*pathogenicity[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/diagnosis/immunology/*therapy/virology[MESH]
  • |Host-Pathogen Interactions[MESH]
  • |Humans[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/diagnosis/immunology/*therapy/virology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box